# MemoryXL Effects on Mild Cognitive Impairment Patients

> **NCT00903695** · PHASE2 · TERMINATED · sponsor: **University of Oklahoma** · enrollment: 10 (actual)

## Conditions studied

- Mild Cognitive Impairment

## Interventions

- **DRUG:** Memory XL
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00903695
- **Lead sponsor:** University of Oklahoma
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-06
- **Primary completion:** 2011-05
- **Final completion:** 2011-05
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** Risk/benefit ratio did not indicate further study would be useful, or fair to future subjects.
- **Last updated:** 2012-01-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00903695

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00903695, "MemoryXL Effects on Mild Cognitive Impairment Patients". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT00903695. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*